Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03635047 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study for Safety and Tolerability of AL002.
A Phase 1 study of Healthy and Alzheimer Disease, sponsored by Alector.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
- 6
- Study locations
NCT03635047 is a Phase 1 study of Healthy and Alzheimer Disease that has completed, run by Alector. The registered enrollment target is 69 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT03635047, a Phase 1 study of Healthy and Alzheimer Disease, has completed, sponsored by Alector.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multi-centre, randomized, double-blind, placebo-controlled, dose escalation first in human (FIH) study in healthy adults and in patients with mild to moderate Alzheimer's disease. The study is designed to systematically assess the safety (including immunogenicity) and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AL002.
Conditions Studied
Interventions
- OTHER Saline Solution
- BIOLOGICAL AL002
Study Locations (6)
Florida
- Brain Matters Research - Delray Beach
- Compass Research - Orlando - Orlando
- Compass Research - The Villages - The Villages
Other
- Nucleus Network Pty Ltd - Melbourne
- University College London - London
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2018-11-12 |
| Est. Completion | 2020-11-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03635047
The ClinicalTrials.gov registry entry for NCT03635047 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The listed sponsor is Alector, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Saline Solution is the first listed.
NCT03635047 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Florida, Other, New York.
Frequently Asked Questions
What is clinical trial NCT03635047 about?
NCT03635047 is a clinical study titled "A Phase I Study for Safety and Tolerability of AL002.". This is a multi-centre, randomized, double-blind, placebo-controlled, dose escalation first in human (FIH) study in healthy adults and in patients with mild to moderate Alzheimer's disease. The study is designed to systematically assess the safety (including immunogenicity) and tolerability, pharmac...
What is the current status of trial NCT03635047?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2018-11-12. Estimated completion is 2020-11-25.
What conditions does trial NCT03635047 study?
This clinical trial studies the following conditions: Healthy, Alzheimer Disease.
What interventions are being tested in trial NCT03635047?
The interventions under investigation include: Saline Solution (OTHER), AL002 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03635047?
This trial is sponsored by Alector, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03635047 being conducted?
This trial has 6 study locations across Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.